Generon (Shanghai) Corporation

Generon (Shanghai) Corporation, which rebranded to Evive Biotech in June 2020, is a biotechnology company focused on developing novel biological therapeutics. Founded in 2004, the firm develops treatments for oncology and inflammatory disorders that are difficult to treat. The company's business model revolves around discovering, developing, and producing biomedicines, specifically therapeutic recombinant proteins, using advanced biotechnologies. It operates with a global outlook, aiming to serve both Chinese domestic and international markets by providing high-quality, affordable biomedicines that meet the regulatory standards of the SFDA, FDA, and EMA.

The company has established cGMP facilities and has operations in the United States, Singapore, and China. Its pipeline includes F-627, a treatment for chemotherapy-induced neutropenia (CIN), and F-652, which is being developed for alcoholic hepatitis (AH) and acute graft-versus-host disease (GVHD). In 2019, the U.S. FDA granted orphan drug status to F-652. In 2021, Evive Biotech and Dr. Xiaoqiang Yan formed a joint venture, ITabMed Ltd., to continue the development of products from the iTAb™ (immunotherapy antibody) platform, which focuses on creating bi- or tri-specific T cell engagers with improved safety profiles.

Keywords: biologics, recombinant proteins, oncology, autoimmune diseases, inflammatory disorders, biomedicine, therapeutic development, cGMP manufacturing, chemotherapy-induced neutropenia, alcoholic hepatitis, graft-versus-host disease, immunotherapy, iTAb platform, bi-specific antibodies, clinical trials, orphan drug